CHAD Therapeutics Launches New Oxygen Conserver And Next-Generation Oxygen Transfilling System
Chatsworth, CA - CHAD Therapeutics, Inc. recently announced the launch of a pneumatic oxygen conserver and its next-generation oxygen transfilling system at the Medtrade show in Las Vegas.
CHAD's BONSAI pneumatic conserver is an important addition to the Company's extensive line of oxygen conserving devices. "With its sleek, lightweight design (less than 10 ounces), conserving ratio of up to 6:1, eight settings, and an adjustable continuous flow feature, BONSAI reinforces CHAD's longstanding leadership in the oxygen conserver market. A pneumatic conserving device that offers a 6:1 savings ratio while ensuring adequate oxygen saturation for patients is a groundbreaking achievement," said President and CEO Earl Yager. CHAD currently expects to receive FDA clearance to market and be able to begin shipping this new device in May.
Yager continued, "CHAD's next-generation oxygen transfilling system, the OMNI line, is a significant upgrade to CHAD's pioneering TOTAL O2 Home Oxygen Delivery System that meets the needs of a broader range of oxygen patients than ever before and gives homecare providers a powerful tool to reduce operating costs and take advantage of the new Medicare transfilling reimbursement category that took effect on January 1, 2007."
The OMNI 2 is designed for the specific requirements of pediatric patients. The OMNI 5 offers increased oxygen delivery of up to 5 liters per minute. In addition to providing stationary oxygen, both devices can also refill a wide variety of portable oxygen cylinders in the patient's home, thus eliminating the cost for the homecare provider and inconvenience for the patient of having to periodically collect and refill oxygen cylinders at a remote depot.
"Our new BONSAI and OMNI devices demonstrate CHAD's commitment to technology that improves patient care while lowering operating costs for homecare providers," the CEO added.
SOURCE: CHAD Therapeutics, Inc.